Comprehensive Treatment of Hematological Patients with SARS-CoV-2 Infection Including Anti-SARS-CoV-2 Monoclonal Antibodies: A Single-Center Experience Case Series

• DOI: 10.3390/curroncol29040188
• Publication Date: 2022-03-28T01:27:51Z
• Authors: Göran Ramin Boeckel; Silke Dorothea Hö...; Christin Bürger; Torid Jacob; Carolin Krekeler; Evgenii Shumilov; Christian Reicherts; Annalen Bleckmann; Georg Lenz; Richard Vollenberg; Phil-Robin Tepasse
• Keywords: Tolerability

Patients with hematologic malignancies are at high risk of exacerbated condition and higher mortality from coronavirus disease 2019 (COVID-19). Bamlanivimab, casirivimab/imdevimab combination, sotrovimab monoclonal antibodies (mABs) that can reduce the COVID-19-related hospitalization. Clinical effectiveness bamlanivimab combination has been shown for Delta variant (B.1.617.2), but latter treatment against Omicron (B.1.1.529) suggested to be reduced. However, tolerability clinical usage severe acute respiratory syndrome 2 (SARS-CoV-2)-specific mABs in patients less specified. We present a retrospective case series analysis all SARS-CoV-2-infected who received SARS-CoV-2-specific our facility between February mid-December 2021. A total 13 COVID-19 (pts) least one malignant diagnosis facility, 3 pts receiving 10 combination. observed SARS-CoV-2 clearance five cases. Furthermore, we reduction necessity oxygen supplementation cases where application was administered off-label. To best knowledge, largest collection anecdotal antibody use hematological malignancies. Potential benefit may reduced duration and/or persistent infection.